Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.32% on an annualized basis producing an average annual return of 18.01%. Currently, AstraZeneca has a market capitalization of $214.04 billion.

Benzinga

AstraZeneca's Ultomiris Shows Sustained Improvements In Functional Activities In Neuromuscular Disease

AstraZeneca Plc (NASDAQ:AZN) shared new and prolonged follow-up results from the Phase 3 CHAMPION-MG trial open-label extension (OLE) of Ultomiris (ravulizumab-cwvz) in generalized myasthenia gravis (gMG). Ultomiris demonstrated long-term efficacy, with improvements in activities of daily living, muscle strength, and quality of life sustained through 60 weeks. Ultomiris was also well tolerated throughout…

Benzinga

Why Big Pharma loves Tim Scott

During the second half of 2021, Scott was the top recipient of drug campaign cash in Congress

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Big Pharma is betting on bigger political ambitions from Sen. Tim Scott

Sen. Tim Scott, a rising star in the Republican Party with broad popularity in his home state of South Carolina, is getting showered with drug industry money before facing voters this fall.

Tribune News Service

How does the COVID-19 prevention drug Evusheld work and who should receive it? An infectious disease specialist explains

The U.S. Food and Drug Administration granted emergency use authorization to AstraZeneca’s COVID-19 antibody drug Evusheld on Dec. 8, 2021. Infectious disease physician Patrick Jackson of the University of Virginia explains how it works, who’s eligible and why some patients are having difficulties accessing it.

The Conversation

LV=’s on board with £511,000 bonus for boss despite shambles of failed sale

Mark Hartigan has been given £511,000 bonus for 2021 – a humbler CEO would have let the dust settle

The Guardian - UK

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Evusheld is becoming hard to find

As immunocompromised people work to get a potentially life saving covid therapy, it's becoming harder to locate

Salon

AstraZeneca steps up to tackle climate change

As the world's leading biopharmaceutical company, AstraZeneca understands how crucial it is to push the boundaries of science and deliver life-changing medicines in record time. The strong dedication to creating a better and healthier future for all, including those living in Thailand, is attested by supplying over 2.8 billion doses…

Bangkok Post

Do I Need A Booster If I’ve Had The Spicy Cough & All Your Other Third Dose Questions Answered

If you're yet to get your third dose of a COVID-19 vaccine, we answer all of your vaccine questions in the below.

Pedestrian.tv

EU regulator advises AstraZeneca's COVID drug be cleared

The European Union's drug regulator says it's recommending that an antibody drug developed by AstraZeneca be authorized to help people avoid getting sick with the coronavirus

The Independent UK

EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld

EMA's human medicines committee (CHMP) has

Benzinga

AstraZeneca's Imfinzi Flunks In Late-Stage Advanced Cervical Cancer Study

AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) and chemoradiotherapy did not achieve the primary goal of improving survival in patients with locally advanced cervical cancer. The Phase 3 study, dubbed "CALLA," tested progression-free survival of patients with the combination against chemoradiotherapy alone. "While the results were not what we hoped for, insights from the trial…

Benzinga

Tragedy as girl, 18, dies of blood clot two weeks after Covid vaccine

Kasey Turner experienced 'thunder clap' headaches from thrombosis in her sinus cavity

Manchester Evening News

Get all your
news in one place.

100’s of premium titles.
One news app.

Bangkok Post

Testament to protecting millions of lives

The race against time to safely develop and quickly deliver a life-saving COVID-19 vaccine around the world serves as AstraZeneca's testament to protecting the lives of billions of people while addressing one of the biggest healthcare crises facing humankind.

Wales Online

Student paramedic, 18, died of clot two weeks after having Covid vaccine

Kasey suffered the worst headache of her life and went to hospital, where she died four days later

Daily Record

'Healthy' teen dies just days after suffering 'thunderclap headache' from Covid jab

Kasey Turner was rushed to intensive care with an acute onset headache last February.

Daily Mirror

'Healthy' teen died after suffering 'thunderclap headache' following AstraZeneca Covid jab

Kasey Turner, 18, died four days after being admitted to Barnsley Hospital, having received her first dose of the AstraZeneca Covid vaccine

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters

European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ: AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections,

Benzinga

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 1.6% on an annualized basis producing an average annual return of 15.33%. Currently, AstraZeneca has a market capitalization of $198.08 billion.

Benzinga

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Squibb Co (NYSE: BMY) claims that AstraZeneca Plc's (NASDAQ: AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint.

Asharq Al-Awsat

AstraZeneca COVID Drug Neutralizes Omicron Sub-Variants in Lab Study

AstraZeneca said on Monday its antibody-based cocktail to prevent and treat COVID-19 retained neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study. This is the first data looking at the impact of AstraZeneca's Evusheld treatment on "cousins" of the Omicron variant following…

The Guardian - UK

Oxford Covid jab gears up for final act: saving the rest of the world

After mishaps and misinformation, jab will build ‘global wall of immunity’, says director of Oxford Vaccine Group

Wales Online

'Do the right thing' Husband who lost wife to AstraZeneca Covid vaccine demands government compensation

Nicola Weideling suffered catastrophic bleeds on her brain after being hospitalised with blood clots caused by the jab

Benzinga

AstraZeneca Mulls Ditching US Approval For Its COVID-19 Vaccine: FT

Citing AstraZeneca Plc's (NASDAQ: AZN) head of research and development, the Financial Times reported that the Company

1 … 19 20 21 22

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.